Search

Your search keyword '"Di Ianni, Mauro"' showing total 5 results
Start Over Author "Di Ianni, Mauro" Journal bone marrow transplantation
5 results on '"Di Ianni, Mauro"'

1. Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

Author

Santoro, Nicole, primary, Mooyaart, Jarl E., additional, Devillier, Raynier, additional, Koc, Yener, additional, Vydra, Jan, additional, Castagna, Luca, additional, Gülbas, Zafer, additional, Martin, José Diez, additional, Araujo, Mercedes Colorado, additional, Kulagin, Alexander, additional, Arat, Mutlu, additional, Arroyo, Concepcion Herrera, additional, Martelli, Maria Paola, additional, Di Ianni, Mauro, additional, Hoogenboom, Jorinde D., additional, de Wreede, Liesbeth C., additional, Ruggeri, Annalisa, additional, and Chabannon, Christian, additional

Published
2022
Full Text
View/download PDF

2. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party

Author

Santoro, Nicole, primary, Mooyaart, Jarl E., additional, Devillier, Raynier, additional, Koc, Yener, additional, Vydra, Jan, additional, Castagna, Luca, additional, Gülbas, Zafer, additional, Martin, José Diez, additional, Araujo, Mercedes Colorado, additional, Kulagin, Alexander, additional, Arat, Mutlu, additional, Arroyo, Concepcion Herrera, additional, Martelli, Maria Paola, additional, Di Ianni, Mauro, additional, Hoogenboom, Jorinde D., additional, de Wreede, Liesbeth C., additional, Ruggeri, Annalisa, additional, and Chabannon, Christian, additional

Published
2022
Full Text
View/download PDF

3. NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models

Author

Baldoni, Stefano, primary, Ruggeri, Loredana, additional, Del Papa, Beatrice, additional, Sorcini, Daniele, additional, Guardalupi, Francesco, additional, Ulbar, Francesca, additional, Marra, Andrea, additional, Dorillo, Erica, additional, Stella, Arianna, additional, Giancola, Raffaella, additional, Fabi, Bianca, additional, Sola, Rosaria, additional, Ciardelli, Sara, additional, De Falco, Filomena, additional, Rompietti, Chiara, additional, Adamo, Francesco Maria, additional, Rosati, Emanuela, additional, Pierini, Antonio, additional, Sorrentino, Carlo, additional, Sportoletti, Paolo, additional, and Di Ianni, Mauro, additional

Published
2021
Full Text
View/download PDF

4. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.

Author

Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, Gülbas Z, Martin JD, Araujo MC, Kulagin A, Arat M, Arroyo CH, Martelli MP, Di Ianni M, Hoogenboom JD, de Wreede LC, Ruggeri A, and Chabannon C

Subjects
Humans, Prospective Studies, Cyclophosphamide therapeutic use, Immunotherapy, Adoptive adverse effects, Lymphocyte Transfusion adverse effects, Lymphocytes, Retrospective Studies, Hematopoietic Stem Cell Transplantation adverse effects, Graft vs Host Disease etiology
Abstract

Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or multiple DLIs after haploidentical-HCT with post-transplant cyclophosphamide (PTCY) at 47 EBMT centers from 2009 to 2018. Indication for DLI was: prophylactic for 59 (34.3%), preemptive for 20(11.6%), and therapeutic for 93(54.1%). For the prophylactic group, the median number of DLIs was 1 (IQR:1-2.5) with a median first dose of 0.1 × 10 6 CD3+ T cell/kg, for the preemptive 2 (IQR:1-3) with 0.5 × 10 6 CD3+ T cell/kg, for the therapeutic 1 (IQR:1-3) with 1 × 10 6 CD3+ Tcell/kg, respectively. OS after first DLI was 61% (46-75%) for prophylactic, 40% (19-61%) for preemptive, and 22% (13-31%) for therapeutic. CI of II-IV aGVHD and cGVHD was 17% (7-27%) and 53% (40-67%) for the prophylactic, 20% (2-38%) and 21% (3-39%) for the preemptive, 17% (9-24%) and 24% (15-33%) for the therapeutic group, respectively. Our data show great variability in the indications and modalities of DLI across responding EBMT centers. Survival rates remain relatively low in patients with active disease. While the cumulative incidence of aGVHD appears acceptable, we showed a high incidence of cGVHD in the prophylactic group, compared with preemptive and therapeutic DLI. These data should be investigated further in prospective clinical trials., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results